Sandoz and mAbxience have entered a global collaboration to develop, manufacture and commercialise a proposed biosimilar to Roche's haemophilia medicine Hemlibra.

GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.

The approval extends Johnson & Johnson’s FcRn-blocking therapy into wAIHA, providing a new targeted treatment for adults with a rare autoimmune blood disorder that can cause severe and persistent haemolytic anaemia.

The 56-week observational findings add longer-term clinical evidence for the eculizumab biosimilar in both complement-inhibitor-naive patients and those previously treated with reference eculizumab.